06855 ASCENTAGE-B
- 17.620
- +0.320+1.85%
ASCENTAGE-B News
Ascentage Pharma to Present Four Studies at US Oncology Meet
Ascentage Pharma Group International (HKG:6855) will present data from four studies at an oncology meeting in the US from May 31 to June 4, according to a Thursday filing with the Hong Kong bourse. Th
Yasheng Pharmaceutical-B (06855): Four studies were selected for the ASCO Annual Meeting, and the latest progress of Nellick's treatment of SDH-deficient GIST was presented orally
Zhitong Finance App News, Yasheng Pharmaceutical-B (06855) issued an announcement. Four clinical studies of the company's three key varieties were selected for the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, and one of them received an oral report. These three key varieties are the first and only third-generation BCR-ABL inhibitor approved for marketing in China, olebatinib (HQP1351; trade name: Nelick), the Bcl-2 selective inhibitor APG-2575, and the FAK/ALK/ROS1 triple inhibitor APG-2449. The annual ASCO annual conference is the field of global oncology
亞盛醫藥-B：2023年報
Ascentage Pharma Chairman Boosts Stake in Firm
Ascentage Pharma Group International (HKG:6855) Chairman Yang Dajun acquired an additional 80,000 ordinary shares in the company for approximately HK$1.4 million or HK$17.08 apiece. According to the f
Yasheng Pharmaceutical-B (06855): Company executives continue to increase their holdings to boost confidence
On April 7, Beijing, Guangzhou, and Zhuhai published documents relating to “Supporting the High-Quality Development of Innovative Pharmaceuticals”. This is only 26 days since the March 13 “Draft for Comments on the Implementation Plan for Full-Chain Support to Support the Development of Innovative Drugs” document went out of the market. In other words, the domestic innovative drug sector felt the strength and warmth of “full chain support” on the policy side in less than a month, reflecting the determination of the regulatory authorities to vigorously develop the innovative drug industry. On April 3 of this year, Yasheng Pharmaceutical was subscribed by Dr. Yang Dajun, the executive director and chairman of the board of directors, and Dr. Wang Shaomeng, the director, for a total of 230,000 shares, equivalent to 41
Yasheng Pharmaceutical-B obtained Executive Director and Chairman Yang Dajun to increase its shareholding by 80,000 shares
Yasheng Pharmaceutical-B (06855) announced that the company was informed by Yang Dajun, the company's executive director and chairman of the board of directors, that on April 5, 2024 and April 8, 2024, he subscribed for a total of 80,000 shares of the company's common shares on the market. The total cost was about HK$1,3662 million. The average price was about HK$17.08 per share, accounting for about 0.028% of the company's total issued share capital at the date of this announcement. On the date of this announcement, according to Part XV of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong, Dr. Yeung was deemed to have used his rights as a beneficial owner, rights held jointly with other persons, and spousal rights
Yasheng Pharmaceutical-B (06855) was increased by 80,000 shares of the company by Executive Director and Chairman Yang Dajun
Yasheng Pharmaceutical-B (06855) issued an announcement. The company was informed by Yang Dajun, the company's executive director and chairman of the board of directors. On 2...
Yasheng Pharmaceutical-B (06855) three research advances unveiled at the 2024 American Association for Cancer Research Annual Meeting
Zhitong Financial App News, Yasheng Pharmaceutical-B (06855) announced three preclinical research results at the 2024 American Association for Cancer Research (AACR) annual meeting, involving the company's original Class 1 drug, olevatinib (trade name: Nelick), MDM2-p53 inhibitor APG-115, FAK/ALK/ROS1 triple tyrosine kinase inhibitor APG-2449, and the embryonic ectodermal development protein (EED) inhibitor APG-5918. The results of the three preclinical studies are as follows: Oreba, a novel multi-target tyrosine kinase inhibitor
Ascentage Pharma Group Directors Acquire Company Shares
Ascentage Pharma Group International (HKG:6855) said Wang Shaomeng, a non-executive director, and Yang Dajun, an executive director, acquired shares of the company on-market, according to a Wednesday
Yasheng Pharmaceutical-B (06855) was subscribed by directors Wang Shaomeng and Yang Dajun for a total of 230,000 shares of the company
Zhitong Finance App News, Yasheng Pharmaceutical-B (06855) issued an announcement. The company was informed by Dr. Wang Shaomeng (Dr. Wang), the company's non-executive director, that on April 2, 2024, he subscribed for a total of 130,000 shares of the company's common shares (shares) on the market. The total cost was about HK$2.3711 million. The average price was approximately HK$18.24 per share, accounting for about 0.045% of the company's total issued share capital on the date of this announcement; and Dr. Yang Dajun (Dr. Yang), the company's executive director and chairman of the board of directors, informed that on April 3, 2024, he acknowledged on the market Purchase a total of 100,000 shares Shares, the total cost is approximately 179
Ascentage Pharma Widens Loss by Nearly 5% in 2023
Ascentage Pharma (HKG:6855) recorded a 4.8% rise in attributable loss for the year ended Dec. 31, 2023, to 925.6 million yuan from 882.9 million yuan during the year-ago period, a Wednesday filing on
Focusing on building a closed loop of global R&D, production and marketing innovation, Yasheng Pharmaceutical-B (06855) is steadily transforming and developing into Biopharma
Relying on systematic advantages formed in various aspects such as global R&D, overseas registration, and market commercialization, Yasheng Pharmaceutical continues to realize its hematopoietic potential while also pushing innovative research and development to a new level, further improving its “positive cycle” of transition to Biopharma.
Yasheng Pharmaceutical-B (06855) Announces 2023 Results Global Clinical Development Ends Harvest Period
Zhitong Finance App News, on March 27, Yasheng Pharmaceutical-B (06855) announced its 2023 annual results: Yasheng Pharmaceuticals achieved total revenue of RMB 222 million during the reporting period. As Nellick, the core product of Yasheng Pharmaceutical, is included in the national medical insurance catalogue and approved for marketing for new indications, as well as by speeding up admission, patient accumulation, and extending the duration of medication, it is expected that more patients will benefit from Nellick's treatment plan, driving sales growth in 2024. Financial reports show that while the commercial self-hematopoietic capacity continues to improve, Yasheng Pharmaceutical is rapidly advancing the patient-centered “global innovation” strategy.
ASCENTAGE-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023
Yasheng Pharmaceutical-B (06855.HK) will hold a board meeting on March 27 to approve the annual results
Gelonghui, March 15, 丨 Yasheng Pharmaceutical-B (06855.HK) announced that the company will hold a board meeting on March 27, 2024 to consider and approve the Group's annual results for the year ended December 31, 2023, and consider paying a final dividend (if any).
ASCENTAGE-B: NOTICE OF BOARD MEETING
Changes in Hong Kong stocks | Yasheng Pharmaceutical-B (06855) is now up nearly 6% and will announce three pre-clinical developments at the American Association for Cancer Research Annual Meeting
Yasheng Pharmaceutical-B (06855) is now up nearly 6%. As of press release, it has risen 5.19% to HK$24.3, with a turnover of HK$23.397,700.
Ascentage Pharma to Present Preclinical Results of Three Anti-Tumor Drugs at US Cancer Meet
Ascentage Pharma (HKG:6855) will present the results of preclinical studies for three drugs at a cancer meeting in San Diego, California in April, according to a Wednesday filing with the Hong Kong bo
Yasheng Pharmaceutical-B (06855): Three pre-clinical advances will be announced at the 2024 American Association for Cancer Research Annual Meeting
Yasheng Pharmaceutical-B (06855) announced that the company selected three preclinical research advances for 2024 American Cancer...
Revenues Not Telling The Story For Ascentage Pharma Group International (HKG:6855)
With a price-to-sales (or "P/S") ratio of 25.1x Ascentage Pharma Group International (HKG:6855) may be sending very bearish signals at the moment, given that almost half of all the Biotechs companies in Hong Kong have P/S ratios under 8.7x and even P/S lower than 2x are not unusual.
Analysis
Price Target
No Data
